United Therapeutics Strikes $525 Million Deal to Eliminate Ralinepag Royalties

PUBT · 20h ago
United Therapeutics Strikes $525 Million Deal to Eliminate Ralinepag Royalties
  • United Therapeutics entered a $525 million upfront agreement with Pfizer subsidiary Arena Pharmaceuticals to eliminate all ralinepag royalty obligations.
  • The amendment removes a low double-digit royalty on net sales of all ralinepag formulations.
  • A $250 million milestone remains payable upon the first US marketing approval of inhaled ralinepag for pulmonary arterial hypertension.
  • A $150 million milestone remains payable upon first oral ralinepag marketing approval for any indication in Japan or specified European markets.
  • Oral ralinepag’s application for pulmonary arterial hypertension remains under FDA review, with a June 24, 2027, user fee action date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104123235) on November 04, 2026, and is solely responsible for the information contained therein.